Afatinib (BIBW2992)

Catalog No.S1011

Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

Price Stock Quantity  
USD 240 In stock
USD 120 In stock
USD 210 In stock
USD 570 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Afatinib (BIBW2992) Chemical Structure

Afatinib (BIBW2992) Chemical Structure
Molecular Weight: 485.94

Validation & Quality Control

Cited by 35 publications:

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

EGFR Inhibitors with Unique Features

  • Selective EGFR Inhibitor

    Erlotinib HCl (OSI-744) EGFR-selective, IC50=2 nM.

  • FDA-approved EGFR Inhibitor

    Lapatinib Approved by FDA for breast cancer.

  • Newest EGFR Inhibitor

    CO-1686 (AVL-301) Irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

  • Classic EGFR Inhibitor

    WZ4002 Mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.

Product Information

  • Compare EGFR Inhibitors
    Compare EGFR Products
  • Research Area
  • Inhibition Profile
  • Afatinib (BIBW2992) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Targets EGFR (L858R) [1]
(Cell-free assay)
EGFR (wt) [1]
(Cell-free assay)
EGFR (L858R/T790M) [1]
(Cell-free assay)
HER2 [1]
(Cell-free assay)
IC50 0.4 nM 0.5 nM 10 nM 14 nM
In vitro BIBW2992 shows potent activity against both wild-type and mutant forms of EGFR and HER2. It is similar to Gefitinib in potency against L858R EGFR, but about 100-fold more active against the Gefitinib resistant L858R-T790M EGFR double mutant. BIBW2992 exhibits potent effects on both EGFR and HER2 phosphorylation in vivo. It compares favorably to reference compounds (such as Lapatinib et al.) in all cell types tested, such as human epidermoid carcinoma cell line A431 expressing wt EGFR, murine NIH-3T3 cells transfected with wt HER2, as well as breast cancer cell line BT-474 and gastric cancer cell line NCI-N87, which express endogenous HER2. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HDLM-2MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3FdHlKSzVyPUCuNFA2PzJizszNM1\MdnNCVkeHUh?=
KASUMI-1NUDVcVFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm[xTWM2OD1yLkCwPVEyKM7:TR?=Mnm1V2FPT0WU
HCC2218NES4[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonXTWM2OD1yLkCwPVg4KM7:TR?=NUPWOXNZW0GQR1XS
KARPAS-45NX7Ob4oxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEP6e|hKSzVyPUCuNFE3PzFizszNMXTTRW5ITVJ?
HSC-4M2G1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXpPJpKUUN3ME2wMlAyPzR6IN88US=>M{XCWnNCVkeHUh?=
CHL-1NV:x[m1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml6xTWM2OD1yLkCxPFM6KM7:TR?=MkTnV2FPT0WU
KY821NUjuWIhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;rTWM2OD1yLkCyNFYh|ryPMoXrV2FPT0WU
NCI-N87MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{Xhb2lEPTB;MD6wNlc4OyEQvF2=NXP1T3N3W0GQR1XS
DOKMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnv5TWM2OD1yLkCzNVk1KM7:TR?=MorUV2FPT0WU
DSH1M4PYNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEO3XXJKSzVyPUCuNFM{OTRizszNNIrHeGdUSU6JRWK=
MDA-MB-175-VIINXfNR2NGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;DRXdjUUN3ME2wMlA{PDF4IN88US=>MYnTRW5ITVJ?
NCI-H2170NXf1VFl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfxWpRKSzVyPUCuNFM4OjhizszNMWPTRW5ITVJ?
BT-474NHn5NnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFPCTldKSzVyPUCuNFQ6QDZizszNMlvvV2FPT0WU
EFO-27NFi4VolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTBwMEWxPFIh|ryPNWjlepExW0GQR1XS
NCI-H720MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;SZZZKSzVyPUCuNFU{OjVizszNM4TLZXNCVkeHUh?=
PC-14M37hOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUPzbm5DUUN3ME2wMlA2PjZ6IN88US=>NEXVSY9USU6JRWK=
EC-GI-10MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTBwMEW5NVIh|ryPM3PWNHNCVkeHUh?=
KYSE-450NIPiSoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFK4b|hKSzVyPUCuNFU6PzhizszNMV3TRW5ITVJ?
BPH-1M2PjW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTBwMEW5PFgh|ryPMX3TRW5ITVJ?
NCI-H292NVfnN5Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTBwME[wPUDPxE1?NGLrNmFUSU6JRWK=
H9MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn6wTWM2OD1yLkC3NVMzKM7:TR?=Mn;QV2FPT0WU
NCI-H526NIrIWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jTUWlEPTB;MD6wO|gzOyEQvF2=MUjTRW5ITVJ?
NCI-H1623M37hWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTi[IhKSzVyPUCuNFgxOjVizszNNH31NpdUSU6JRWK=
KYSE-140MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnr5TWM2OD1yLkC4N|Mh|ryPMVXTRW5ITVJ?
Ca9-22M2Tpbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjlUphqUUN3ME2wMlA5OzV|IN88US=>MV3TRW5ITVJ?
AU565MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHnQfYhKSzVyPUCuNFg2ODRizszNMkjmV2FPT0WU
ZR-75-30NHHiR2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2DLXGlEPTB;MD6wPVU1PSEQvF2=MlHUV2FPT0WU
NCI-H1770MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PVcmlEPTB;MD6xNFI5KM7:TR?=M1G2UnNCVkeHUh?=
LB2241-RCCM3rhPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nIOmlEPTB;MD6xNFg5PCEQvF2=NYi3NmtQW0GQR1XS
CAL-39NH\FfmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXX4SpFJUUN3ME2wMlEyPzl{IN88US=>NYG2V2p7W0GQR1XS
UACC-893M3fSc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HaZWlEPTB;MD6xNVg5PSEQvF2=NFTV[pBUSU6JRWK=
LU-65M4W4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDPe3BKSzVyPUCuNVI3OzNizszNNVvK[GptW0GQR1XS
HNMkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3qwZWlEPTB;MD6xN|A4PyEQvF2=MWfTRW5ITVJ?
TI-73NGm5XoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHrOZ29KSzVyPUCuNVQ4OTVizszNMl[wV2FPT0WU
KU812MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIL0epJKSzVyPUCuNVU1PTZizszNMWTTRW5ITVJ?
SW13MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWjnPXV4UUN3ME2wMlE3OjF4IN88US=>MlPQV2FPT0WU
BB30-HNCM3\jRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTBwMU[1O|Yh|ryPM2XDfXNCVkeHUh?=
HSC-2MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTBwMU[4N|ch|ryPNWj0[IVsW0GQR1XS
BV-173M3e3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFe5UmxKSzVyPUCuNVc2QTZizszNM1LtW3NCVkeHUh?=
CAL-27M3Ps[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXJWVQ6UUN3ME2wMlE4PjN4IN88US=>MVjTRW5ITVJ?
SBC-1NV\HTFVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTBwMUi5OVkh|ryPNYL5Nm9rW0GQR1XS
CAL-33MnrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnpTWM2OD1yLkKwNVg1KM7:TR?=Mm[zV2FPT0WU
NCI-H209MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33IemlEPTB;MD6yNFQ3KM7:TR?=MnTwV2FPT0WU
COR-L105M4\Fc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3[0NmlEPTB;MD6yNVA5PCEQvF2=M2jsZXNCVkeHUh?=
HSC-3NIHZRmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTKUVZoUUN3ME2wMlIyOTl6IN88US=>MYLTRW5ITVJ?
NCI-H69NXX6VZN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1P1fGlEPTB;MD6yNVQ2OSEQvF2=Mm\QV2FPT0WU
MOLT-13NXHPbXJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTBwMkO5O|Uh|ryPMlrjV2FPT0WU
ML-2MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2fUdmlEPTB;MD6yOFgxOiEQvF2=NYHqOXpIW0GQR1XS
IGROV-1NXn6bpRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTBwMkW5OVIh|ryPMmfEV2FPT0WU
TK10NIC0TJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zMNGlEPTB;MD6yOlc{QCEQvF2=NFTiZ4hUSU6JRWK=
EoL-1-cellNIi1d45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLTOGhKSzVyPUCuNlY5QTJizszNNV7BVnhVW0GQR1XS
HO-1-N-1NWHiVVVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXUTWM2OD1yLkK3PFU{KM7:TR?=NV3LUpVwW0GQR1XS
BHYM33CSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXITWM2OD1yLkK4OlU2KM7:TR?=MWjTRW5ITVJ?
LU-139NWW0PYVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDkTWM2OD1yLkOwOVEh|ryPNGH1PIVUSU6JRWK=
23132-87NXXRXIQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTBwM{G5NlMh|ryPNUTuOnhjW0GQR1XS
ACHNNF7nOWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIn3ZohKSzVyPUCuN|E6QTRizszNNVfDV|Y4W0GQR1XS
DoTc2-4510M4Oxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkL4TWM2OD1yLkOyNlE6KM7:TR?=MWrTRW5ITVJ?
BB65-RCCM1jz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTBwM{S1PVMh|ryPNH7VU4hUSU6JRWK=
HLEMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn\JTWM2OD1yLkO1NFQ3KM7:TR?=M1zSfnNCVkeHUh?=
HCC1419MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPMTWM2OD1yLkO2OFA5KM7:TR?=NH\ab|VUSU6JRWK=
A388NV3IeppnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTBwM{[4OVch|ryPMV3TRW5ITVJ?
NUGC-3M3fWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGWzNHBKSzVyPUCuN|g{PzNizszNMYfTRW5ITVJ?
KYSE-180MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zBfGlEPTB;MD6zPVA5QSEQvF2=MX7TRW5ITVJ?
TE-6M1PpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlzYTWM2OD1yLkSwNlQ3KM7:TR?=NFH0eZFUSU6JRWK=
A498M3TIdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFvMXVNKSzVyPUCuOFA3PzRizszNMmjnV2FPT0WU
NCI-H1648M3LjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2rhSmlEPTB;MD60OFE5OiEQvF2=MYnTRW5ITVJ?
DU-145MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3fHemlEPTB;MD60OFg{OyEQvF2=MmP5V2FPT0WU
CW-2NVTGUm5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDFSGIzUUN3ME2wMlQ3QTF2IN88US=>NXW1[HJwW0GQR1XS
A431MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{nJSGlEPTB;MD60PFI{OyEQvF2=MVXTRW5ITVJ?
SASM2TGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2rXfGlEPTB;MD60PFM6QCEQvF2=MVLTRW5ITVJ?
NCI-H2126M1\vRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTBwNUG5NlYh|ryPNUjIXmd{W0GQR1XS
NCI-H358NXfBO|g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHe2OY1KSzVyPUCuOVMzOSEQvF2=NGOyUG9USU6JRWK=
FADUM4\qc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHL3eItKSzVyPUCuOVQ1ODRizszNMle2V2FPT0WU
ACNNUnSTWdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4jGR2lEPTB;MD61OVA6PCEQvF2=MWfTRW5ITVJ?
HCC70M36wVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3aOlQ6UUN3ME2wMlU4PjZzIN88US=>MXvTRW5ITVJ?
NCI-H1838NUnlOlJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXXLbnZ4UUN3ME2wMlYxOjl7IN88US=>NWWxSmFvW0GQR1XS
CAL-54MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHXT2c5UUN3ME2wMlYyPjJzIN88US=>NGfTNm9USU6JRWK=
NCI-H1975MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPuOJBsUUN3ME2wMlYyPzJ6IN88US=>NIPjTI9USU6JRWK=
COR-L88NVnaOodiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmTuTWM2OD1yLk[0NVE{KM7:TR?=NEfJVGhUSU6JRWK=
CTV-1NWf4enp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\kemlEPTB;MD62OFM6OiEQvF2=NI[5Zm9USU6JRWK=
EW-18NWjOUZZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGfXcYhKSzVyPUCuOlg3QThizszNM33o[nNCVkeHUh?=
HCC1806NW[0N5VZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfPfY0zUUN3ME2wMlY6PjZ4IN88US=>MVfTRW5ITVJ?
HuP-T4MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEfrdVdKSzVyPUCuOlk4PiEQvF2=MWLTRW5ITVJ?
MDA-MB-361NYH3cIJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTBwN{K2OlIh|ryPNHT3TlFUSU6JRWK=
NCI-H1573MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTBwN{O2N{DPxE1?MUTTRW5ITVJ?
KU-19-19M3;sVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2DhcWlEPTB;MD63O|Q3PCEQvF2=NHjweW1USU6JRWK=
COLO-678MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlj3TWM2OD1yLkiwPFM1KM7:TR?=M1HjfXNCVkeHUh?=
C-33-ANV34R2tvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTBwOEGyPVch|ryPNWjXU2FSW0GQR1XS
Calu-3M323W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7BdI1KSzVyPUCuPFE1OzRizszNM2mwXnNCVkeHUh?=
AGSMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHq3N2dKSzVyPUCuPFM3PDhizszNM{nkd3NCVkeHUh?=
SCC-25NH;OU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkHiTWM2OD1yLki0NVcyKM7:TR?=NYfUS2pxW0GQR1XS
JVM-2MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3S1NGlEPTB;MD64PFI6QSEQvF2=M1q3e3NCVkeHUh?=
HCE-TMn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHztPFRKSzVyPUCuPFg1OjhizszNNGTzTXhUSU6JRWK=
ES4M1LOcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{HpNGlEPTB;MD65O|g{PiEQvF2=M{jUOXNCVkeHUh?=
EKVXNU\iSmUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTFwMEGwOlQh|ryPNUPC[XRjW0GQR1XS
D-542MGM1nPbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnu2TWM2OD1zLkCxNFY1KM7:TR?=MmPYV2FPT0WU
SW1116NXG5bVh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmPKTWM2OD1zLkCxNlg4KM7:TR?=NULlVYE5W0GQR1XS
5637NHGyV4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\6SGlEPTB;MT6wNVUyKM7:TR?=MYDTRW5ITVJ?
HT-1376NEjUWZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvnVG5KSzVyPUGuNFE2OTNizszNMVPTRW5ITVJ?
NB69NETrepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mni3TWM2OD1zLkCyPVQ2KM7:TR?=MYfTRW5ITVJ?
YKG-1M1;Q[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTFwMEW0NVkh|ryPNFjoR3pUSU6JRWK=
EW-3MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTFwMEe4PFMh|ryPM{PveXNCVkeHUh?=
GCIYM{HNOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3naemlEPTB;MT6wPFExPCEQvF2=NXrtcJh4W0GQR1XS
SK-MES-1NHzOeYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTFwMUG0PFch|ryPMlTxV2FPT0WU
PANC-08-13NIrVfWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXUcmtKSzVyPUGuNVY1OTZizszNM2jlU3NCVkeHUh?=
SK-NEP-1NV3aUIFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVnWVmMyUUN3ME2xMlE4PTF|IN88US=>NYjVeoN{W0GQR1XS
SW954NIDrbmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHrLR2RKSzVyPUGuNlAzOTRizszNM4nwUXNCVkeHUh?=
NCI-SNU-5MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTFwMkO5JO69VQ>?NYLYeHpZW0GQR1XS
SW48M{G1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWX3S403UUN3ME2xMlI2PDN{IN88US=>NHLtTGtUSU6JRWK=
HT-3Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHJOJpJUUN3ME2xMlI5PzV|IN88US=>MUnTRW5ITVJ?
ETK-1Ml65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVf3cXJLUUN3ME2xMlM4PDV4IN88US=>MVnTRW5ITVJ?
SCC-15MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HPVmlEPTB;MT6zPVQ2OSEQvF2=NYPNUnY4W0GQR1XS
DU-4475MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTFwNECxNlEh|ryPMnjsV2FPT0WU
NB5NES4WpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTFwNEGzNVch|ryPNXHnTFM1W0GQR1XS
CFPAC-1NH24[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnxTWM2OD1zLkSyOFk{KM7:TR?=M3;MeXNCVkeHUh?=
NCI-H630MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1zLSmlEPTB;MT60OVU5OiEQvF2=M4DSRXNCVkeHUh?=
NCI-H82Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG[2e45KSzVyPUGuOVQxODZizszNNGLlZmRUSU6JRWK=
ECC10NYjrUotLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mni1TWM2OD1zLkW1N|Y6KM7:TR?=M{HuZ3NCVkeHUh?=
K5M{fFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVyy[oVUUUN3ME2xMlU5OzV5IN88US=>MWLTRW5ITVJ?
ME-180NWPs[YlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGKwXIRKSzVyPUGuOlExQTZizszNNHnDT45USU6JRWK=
KYSE-410NXP2UnhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfoTWM2OD1zLk[1OlczKM7:TR?=MX\TRW5ITVJ?
G-401MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\kUJpxUUN3ME2xMlY4PDF|IN88US=>MnPLV2FPT0WU
TGBC24TKBNHTXZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWSyXGNzUUN3ME2xMlY5OjNizszNNXXRZ|RZW0GQR1XS
Detroit562M2Pqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU[zWGV4UUN3ME2xMlcxOTV{IN88US=>NHe2VXJUSU6JRWK=
OE19NEi1NY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXxTWM2OD1zLkexOVEzKM7:TR?=NFzuTmZUSU6JRWK=
CAKI-1M1HD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rPfmlEPTB;MT63PFIyOSEQvF2=NVLBZW9DW0GQR1XS
TE-12M1vsc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\3[GlEPTB;MT64NFQyPCEQvF2=MXzTRW5ITVJ?
NCI-H1666M2XxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFS0b4FKSzVyPUGuPFA6PDhizszNMWfTRW5ITVJ?
TE-1M2HoWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;lfmlEPTB;MT64NVQ4PSEQvF2=Mo\qV2FPT0WU
CAL-12TMmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVzZSJFmUUN3ME2xMlg5QTR3IN88US=>M1LLUHNCVkeHUh?=
TE-8MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTFwOUGzO|ch|ryPMmXHV2FPT0WU
KYSE-270M4PlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWPsSZZZUUN3ME2yMlAzPzN{IN88US=>MXTTRW5ITVJ?
GMS-10NYjicGR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PoeWlEPTB;Mj6wN|UyPyEQvF2=MVLTRW5ITVJ?
A2780M3vkb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTJwME[yPVQh|ryPMmnpV2FPT0WU
OMC-1Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTJwMEixOlkh|ryPNWjLOJFOW0GQR1XS
LoVoMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\WfmlSUUN3ME2yMlExPzl5IN88US=>NWe0dohJW0GQR1XS
PANC-03-27M4rzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXrLPGJsUUN3ME2yMlE3PjNzIN88US=>MYrTRW5ITVJ?
MDA-MB-157NWXsRnRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4jscGlEPTB;Mj6yNVgzQCEQvF2=MUDTRW5ITVJ?
CaR-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHTcJBKSzVyPUKuNlgzQDFizszNNEXNSmxUSU6JRWK=
769-PMnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXkTWM2OD1{LkK5NFM4KM7:TR?=NXrvdXpYW0GQR1XS
NB7M4OxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nhSmlEPTB;Mj6yPVY4PiEQvF2=MWrTRW5ITVJ?
MKN7Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3zKZWlEPTB;Mj6zOVM{PSEQvF2=M4DOOXNCVkeHUh?=
NCI-H1048MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;PNWlEPTB;Mj60PVE2QCEQvF2=MofXV2FPT0WU
RCM-1M2GzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXrodVRSUUN3ME2yMlUzQTN6IN88US=>NVn2WpJRW0GQR1XS
HT55NHzHUphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTJwNUezPEDPxE1?NWThWZpZW0GQR1XS
HCC1569NV30eWhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVLsU5l6UUN3ME2yMlU5Ojl5IN88US=>NHjsXXdUSU6JRWK=
LXF-289NXTucHJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkX1TWM2OD1{Lk[zOVY2KM7:TR?=NX3JR4VSW0GQR1XS
OVCAR-3MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2XLd2lEPTB;Mj62O|E3PyEQvF2=MXTTRW5ITVJ?
TE-10M3eyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTvNXJUUUN3ME2yMlY5ODd6IN88US=>Ml;HV2FPT0WU
SNU-C2BNIG0V21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTJwNki2NVYh|ryPM1PJWnNCVkeHUh?=
LB1047-RCCMn7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXPXnpbUUN3ME2yMlc1QDh6IN88US=>M2Hk[3NCVkeHUh?=
SN12CMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU\5TI5YUUN3ME2yMlkyQTZ2IN88US=>MVjTRW5ITVJ?
786-0NF\udnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXvS5FKSzVyPUOuNFY1ODhizszNM1jWVnNCVkeHUh?=
HT-29MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlGwTWM2OD1|LkC3N|A6KM7:TR?=Mlv0V2FPT0WU
RPMI-7951NYDKN5JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{TQPWlEPTB;Mz6wO|U6KM7:TR?=MnPQV2FPT0WU
NBsusSRMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nCXWlEPTB;Mz6xPFI2PCEQvF2=MVTTRW5ITVJ?
NKM-1MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{n4[WlEPTB;Mz6xPFc1PCEQvF2=M{TGfnNCVkeHUh?=
Capan-2NXXWWVViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHNTWM2OD1|LkS2PFc2KM7:TR?=NVzDRnZ7W0GQR1XS
MKN1M3XRZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFH4NHRKSzVyPUOuOFcyODhizszNNU\qUnk2W0GQR1XS
OAW-42NGHrOYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTNwNUCwNlYh|ryPMVjTRW5ITVJ?
SKG-IIIaMk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4iybmlEPTB;Mz61NlI{PyEQvF2=NHnZbWtUSU6JRWK=
no-11NHG3NYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEK0U2ZKSzVyPUOuOVM2PjRizszNNVrY[GJ4W0GQR1XS
NYNHnmeWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlu4TWM2OD1|LkWzOlU2KM7:TR?=MUfTRW5ITVJ?
HEC-1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7lVXBzUUN3ME2zMlU5QTVizszNNYm4TnVlW0GQR1XS
NCI-H441NGHSWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\YfmlEPTB;Mz61PVg1OSEQvF2=M{HJTnNCVkeHUh?=
NCI-H2009MlPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\OeWlEPTB;Mz62NVIyPiEQvF2=M33hWHNCVkeHUh?=
T47DNWriXG42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3TxW2lEPTB;Mz62NlIyPyEQvF2=NWXmbZA2W0GQR1XS
SNU-449MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXGTWM2OD1|Lk[1PFI3KM7:TR?=NEPO[4NUSU6JRWK=
NCI-SNU-1MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXSTWM2OD1|Lk[5O|M2KM7:TR?=M4XRSHNCVkeHUh?=
BT-20MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTNwNkm3PVUh|ryPNIq0dZdUSU6JRWK=
LS-123NW\GRYE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHn0U3RKSzVyPUOuO|QzQDRizszNNV\oRYRmW0GQR1XS
8305CNXzVeHJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLj[mZWUUN3ME2zMlc2QTFzIN88US=>M4ToXnNCVkeHUh?=
OCUB-MMn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTNwN{[xPFch|ryPM{DHVXNCVkeHUh?=
KOSC-2M3vHfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M376e2lEPTB;Mz64N|Q2OSEQvF2=MljlV2FPT0WU
NCI-H1693NInKeJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjXd2ZOUUN3ME2zMlg1OThzIN88US=>NILXTHZUSU6JRWK=
TE-9M4X1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUK5N2pXUUN3ME2zMlg1Ozh{IN88US=>MnX2V2FPT0WU
MV-4-11MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFL0To9KSzVyPUOuPFc6QTRizszNM{ewV3NCVkeHUh?=
GAMGNHnkPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIHPSHRKSzVyPUOuPVE{OTRizszNNXXzW4d5W0GQR1XS
KNS-62NIjuUZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4W4e2lEPTB;Mz65OFc{OSEQvF2=NF3ERpNUSU6JRWK=
MC116MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3X1ZWlEPTB;Mz65OVQ5QSEQvF2=NVvJOIZlW0GQR1XS
647-VNGi2boxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYewdohyUUN3ME2zMlk5PDV{IN88US=>MV7TRW5ITVJ?
U-87-MGMn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MofiTWM2OD12LkGwOFgyKM7:TR?=M4TqcXNCVkeHUh?=
RPMI-8226MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHQTWM2OD12LkGxOlMyKM7:TR?=NEfqV2FUSU6JRWK=
SW1417MlP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIL3bZJKSzVyPUSuNVIyPDdizszNM3v4WnNCVkeHUh?=
LAMA-84M2n1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2O3V2lEPTB;ND6xO|AzKM7:TR?=MoDDV2FPT0WU
LS-513M4LNZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLBTWM2OD12LkOxNlE4KM7:TR?=NXHCVYxKW0GQR1XS
KLENY\j[Y54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDZTWM2OD12LkSwPFE6KM7:TR?=NUmwbXZkW0GQR1XS
HCT-116NVLCfGJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVX3VmhlUUN3ME20MlQyODB5IN88US=>NGSyUZhUSU6JRWK=
EPLC-272HM{\0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2DTZWlEPTB;ND60NVU{OyEQvF2=MnfGV2FPT0WU
KS-1M4XLTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTRwNUC4PFkh|ryPM2K3U3NCVkeHUh?=
HT-1197MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHPVZnhKSzVyPUSuOVI3PjlizszNNYTKPIZNW0GQR1XS
LCLC-97TM1NWXTU5NYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTRwNUO2PFYh|ryPM3nNTnNCVkeHUh?=
ES5MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1\DXWlEPTB;ND64N|czOyEQvF2=MlnXV2FPT0WU
CTB-1MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlHmTWM2OD12Lki0PFgh|ryPNHXCZ5BUSU6JRWK=
HL-60MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnviTWM2OD12Lki2OlEyKM7:TR?=MVHTRW5ITVJ?
VM-CUB-1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXO[lRjUUN3ME20Mlg3QDF7IN88US=>NXPlTG5FW0GQR1XS
MEG-01M3KyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjuZYhKSzVyPUSuPVk1ODNizszNNXLwXGQzW0GQR1XS
KYSE-520NVnFd3UzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTyUpdpUUN3ME21MlIxQDN7IN88US=>MYTTRW5ITVJ?
HuO-3N1NInU[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XDWGlEPTB;NT6yOFA1OyEQvF2=M1;ObHNCVkeHUh?=
SW620MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PrOWlEPTB;NT6yOFk3PCEQvF2=NGrSVY9USU6JRWK=
U031Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVP6bGRmUUN3ME21MlI2PDJ2IN88US=>MUXTRW5ITVJ?
TE-5NWnHVm97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkDwTWM2OD13LkSwPFUh|ryPMmKxV2FPT0WU
NCI-H747Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MofzTWM2OD13LkSyOFczKM7:TR?=MXnTRW5ITVJ?
MG-63NH\qfZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIjqNIpKSzVyPUWuOFg4PjJizszNNFHDcYdUSU6JRWK=
HC-1NHn4W5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vMNWlEPTB;NT61NVg{QSEQvF2=MYDTRW5ITVJ?
HCC2998MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVThNnNMUUN3ME21MlUzPjF3IN88US=>NXHNZnNYW0GQR1XS
NTERA-S-cl-D1M3i5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPxWYRKSzVyPUWuOVQ2OzdizszNNX;l[HlMW0GQR1XS
KINGS-1NXf2XmZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\0S2VVUUN3ME21MlYxQTR2IN88US=>NFSxeYtUSU6JRWK=
D-423MGNXrETXNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXlTWM2OD13Lk[xO|A2KM7:TR?=NWHheYRGW0GQR1XS
SW962NHzoOFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;oZ5pkUUN3ME21MlYzODN{IN88US=>MkPwV2FPT0WU
LOXIMVINHPobGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;mfmlEPTB;NT62N|g4OyEQvF2=M2O0dXNCVkeHUh?=
LS-411NNF;meGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXWVlZKSzVyPUWuO|k1PDFizszNM3PaPHNCVkeHUh?=
NCI-H2291M1rwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MojITWM2OD13Lkm4PVQ{KM7:TR?=Mo[zV2FPT0WU
A549Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWXCUnNzUUN3ME22MlEzPTV|IN88US=>MoW4V2FPT0WU
LS-1034MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTU[XN6UUN3ME22MlIxPzB4IN88US=>NI\FWGJUSU6JRWK=
NB14M{PpOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nxVmlEPTB;Nj60N|g{PiEQvF2=NF7JZYdUSU6JRWK=
NCI-H1299M4T3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXjZSpRVUUN3ME22MlY{OTdzIN88US=>M{Lm[XNCVkeHUh?=
BT-549M2XDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\UTWM2OD14Lk[2PFg6KM7:TR?=NVO4WZFOW0GQR1XS
J-RT3-T3-5MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLlTWM2OD14Lki2PUDPxE1?NXLtOnpSW0GQR1XS
SW756NVv4[ZVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnYTWM2OD14LkmxNVc3KM7:TR?=M{XUSHNCVkeHUh?=
DJM-1NWnDcpJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M161cmlEPTB;Nj65NlAyOiEQvF2=NV3UUXlMW0GQR1XS
GP5dNFT4bIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDWTWM2OD14Lkm3N|k1KM7:TR?=MW\TRW5ITVJ?
MOLT-4NIOxfGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWG5OVc1UUN3ME23MlAzOTN3IN88US=>NUfROYxvW0GQR1XS
NCI-H28MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2G4[mlEPTB;Nz6xOlQxPSEQvF2=MVzTRW5ITVJ?
MN-60NYWxelZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\wTWM2OD15LkK4NFg6KM7:TR?=MoXxV2FPT0WU
RMG-IMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTdwM{myPVYh|ryPMmjuV2FPT0WU
COLO-800M3P6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTdwNEG0OFYh|ryPNVjPW|QxW0GQR1XS
DBMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUm4cVNrUUN3ME23MlYyODB3IN88US=>NE\2THdUSU6JRWK=
Ca-SkiM4PPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmXXTWM2OD15Lk[0NlU6KM7:TR?=NXnwZYtiW0GQR1XS
HELNH\xUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M335W2lEPTB;Nz63NVIxOyEQvF2=NWDuOGxvW0GQR1XS
NH-12M1rFTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUHqSXRGUUN3ME23MlczQDB6IN88US=>MVvTRW5ITVJ?
LB373-MEL-DMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTdwN{[3O|Eh|ryPMUfTRW5ITVJ?
SW900NVrnOJd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTdwOEKxNlEh|ryPM3\ZW3NCVkeHUh?=
JVM-3NIjNVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoDkTWM2OD15Lki5OVk6KM7:TR?=M4WyNnNCVkeHUh?=
OAW-28NX3DW3o3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojiTWM2OD15Lkm0OVc5KM7:TR?=MmPKV2FPT0WU
KURAMOCHIMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XJfmlEPTB;Nz65OFgyOSEQvF2=NFHtZ2JUSU6JRWK=
BE-13NYHGfXNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPyUmZKSzVyPUeuPVgyOTJizszNNFvZWVJUSU6JRWK=
VMRC-RCZM4TGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoD3TWM2OD16LkCxOlk4KM7:TR?=M{jlcnNCVkeHUh?=
NCI-H727M3zvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37ZPWlEPTB;OD6xNFQzKM7:TR?=MVTTRW5ITVJ?
SW1710MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{C3[WlEPTB;OD6xPFUyPSEQvF2=MofiV2FPT0WU
D-502MGNUfoRpRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml[xTWM2OD16LkK5NlgzKM7:TR?=M1jxXHNCVkeHUh?=
NCI-H1993M4jLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWftZm5tUUN3ME24MlM{PjNzIN88US=>NEPFVmlUSU6JRWK=
SCC-4NVH0fJRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULQ[4RuUUN3ME24MlQ1ODV7IN88US=>MV3TRW5ITVJ?
HAL-01Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWjxdndbUUN3ME24MlUyQTFizszNNYLvRmNkW0GQR1XS
GT3TKBNVjpWI5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRThwNke5OlQh|ryPMUjTRW5ITVJ?
SK-OV-3M17ac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRThwN{GzNlkh|ryPM1LBO3NCVkeHUh?=
COLO-829NUizXZFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRThwOEC5O|Yh|ryPNVvkWlF1W0GQR1XS
OCI-AML2NUK5[VlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HhXWlEPTB;OD65OVQ5OSEQvF2=M1XEUHNCVkeHUh?=
OS-RC-2MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkGxTWM2OD17LkCyNVkh|ryPM{TUOXNCVkeHUh?=
BFTC-909MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTCSWQ6UUN3ME25MlA3Pzl7IN88US=>Mm\ZV2FPT0WU
EW-11NXTpd2c1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M37T[GlEPTB;OT6xO|Y2OyEQvF2=MUPTRW5ITVJ?
HCE-4MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG[xc4dKSzVyPUmuNlE2PThizszNMkXyV2FPT0WU
BALL-1MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn7jTWM2OD17LkKxPVA4KM7:TR?=MoW0V2FPT0WU
SF539NIfoZnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTlwMkO1OlIh|ryPNGHsZYZUSU6JRWK=
CAMA-1Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXXfFc2UUN3ME25MlI5OTJ6IN88US=>NGjZbYdUSU6JRWK=
C32NV\1O5VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4nXe2lEPTB;OT6zN|A3PCEQvF2=MUfTRW5ITVJ?
NCI-H1703Mon0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmflTWM2OD17LkO0N|c2KM7:TR?=MkfzV2FPT0WU
NCI-H1650M2DWO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTlwNkC5OFYh|ryPMUPTRW5ITVJ?
NCI-H1563MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3W4TGlEPTB;OT63OlA{OSEQvF2=M1XIcXNCVkeHUh?=
CAL-85-1MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\tTWM2OD17Lki3N|g{KM7:TR?=MXLTRW5ITVJ?
UM-UC-3M2HxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mny3TWM2OD17Lkm1NFMh|ryPNXXzW3RGW0GQR1XS
BxPC-3NXfrVmlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLDOGxKSzVyPUGwMlA6PzJizszNNHHSd5BUSU6JRWK=
MHH-PREB-1MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7CTWM2OD1zMD6xPVk6KM7:TR?=NXPpV4JLW0GQR1XS
DELNXn2c4FmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUfBO5o2UUN3ME2xNE4{QTR4IN88US=>MYXTRW5ITVJ?
HuCCT1MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGX2fGhKSzVyPUGwMlYxOzNizszNM4frTHNCVkeHUh?=
OVCAR-4NX\rSm5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\PTWM2OD1zMD64PFM2KM7:TR?=NEnSXWhUSU6JRWK=
CAL-72MkHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkXCTWM2OD1zMD65N|kyKM7:TR?=MoPYV2FPT0WU
HCC1954M13Kemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fhSWlEPTB;MUGuNFc2PCEQvF2=NIfkSIhUSU6JRWK=
EFO-21NY\NV2xnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{P1U2lEPTB;MUGuNVA1PSEQvF2=M3HXZXNCVkeHUh?=
FTC-133M1n5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIr6[XNKSzVyPUGxMlE1ODdizszNM1;jV3NCVkeHUh?=
SK-MEL-24M2L2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTFzLkKzOlYh|ryPNGDjPVhUSU6JRWK=
UACC-62M1\xcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnnRlhqUUN3ME2xNU4zOzZ6IN88US=>MYHTRW5ITVJ?
NCI-H650NF7zeopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYjJR|UxRTFzLkK0NVgh|ryPMl7rV2FPT0WU
ALL-POMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX\qdFRyUUN3ME2xNU4zPTF{IN88US=>MXvTRW5ITVJ?
T84NVLCbG9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTFzLkO5NFch|ryPMYrTRW5ITVJ?
IST-MEL1NIK3fZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDEbY1KSzVyPUGxMlQ2PTlizszNM4nGVXNCVkeHUh?=
SW626NFXvbJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFL2fItKSzVyPUGxMlU4PTVizszNNIHOV2dUSU6JRWK=
RPMI-2650M1nFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTFzLkW4PFUh|ryPNInBd4lUSU6JRWK=
MC-IXCMlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7CSFd1UUN3ME2xNU43PzJ6IN88US=>NU\pNnRDW0GQR1XS
HOP-62MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3fvUGlEPTB;MUGuOlc3PCEQvF2=M4fpO3NCVkeHUh?=
NOS-1M3LxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHTTb|lKSzVyPUGxMlcyODlizszNMXnTRW5ITVJ?
SW1573MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;GcmxPUUN3ME2xNU44Ojl3IN88US=>MXnTRW5ITVJ?
WM-115M12xeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HuOGlEPTB;MUGuO|U5QCEQvF2=NVfmfnVGW0GQR1XS
HuO9MlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXhU5ptUUN3ME2xNU45Pzd2IN88US=>MYfTRW5ITVJ?
YAPCNWr4flZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTFzLkmyOVkh|ryPMnjVV2FPT0WU
MDA-MB-453NFu1N2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3voOGlEPTB;MUGuPVUyPSEQvF2=MlnTV2FPT0WU
NCI-H596MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NID4S41KSzVyPUGyMlA{PjlizszNNF\MXZBUSU6JRWK=
A172Mn\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTF{LkC3PVgh|ryPNEP2WnRUSU6JRWK=
RS4-11MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYe2W3FWUUN3ME2xNk4yPzJ3IN88US=>MYDTRW5ITVJ?
HCC1937M{\1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTF{Lke1OlQh|ryPMlTJV2FPT0WU
SW837NX;EbIlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;LU4h4UUN3ME2xNk46ODJ6IN88US=>Ml;6V2FPT0WU
NMC-G1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;obphKSzVyPUGyMlkzOzRizszNNGrO[FhUSU6JRWK=
PFSK-1NF:0N4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIrhVFZKSzVyPUGzMlA3KM7:TR?=NUDqbos4W0GQR1XS
DBTRG-05MGM36wZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTF|LkC2N|Ih|ryPM131ZnNCVkeHUh?=
SK-UT-1NEDtV5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTF|LkGwPFMh|ryPMn\hV2FPT0WU
OVCAR-5M3n6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTF|LkG1PVMh|ryPMYDTRW5ITVJ?
8505CNX7MXHMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjwenJKSzVyPUGzMlIxPjdizszNNXjONlBrW0GQR1XS
SK-MEL-1Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlrrTWM2OD1zMz63NVM2KM7:TR?=NHzVd41USU6JRWK=
LK-2M{DDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\0TWM2OD1zMz63OlM6KM7:TR?=NUSzZW1TW0GQR1XS
OE33M4DmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXJO5RWUUN3ME2xN{44QDZizszNNW\qNphpW0GQR1XS
Ramos-2G6-4C10NGfMe2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXDW|lKSzVyPUG0MlAzODJizszNMljwV2FPT0WU
EW-13NYrDcFByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLpdmN[UUN3ME2xOE4xOzV{IN88US=>NXK1XFlEW0GQR1XS
NCI-H1793NUP0fodkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmrDTWM2OD1zND6yNFg4KM7:TR?=MmXZV2FPT0WU
BHT-101NIDF[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVu1RnRIUUN3ME2xOE4zPDFizszNNELIdVVUSU6JRWK=
RKONXfuWFNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTF2LkWwO|Uh|ryPNWq4OmZrW0GQR1XS
NEC8MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTF2LkW0O|Ih|ryPMlSwV2FPT0WU
PANC-10-05MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1:5TmlEPTB;MUSuOlI1PyEQvF2=MkW5V2FPT0WU
NCI-H2030NFrmVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVj2cm1CUUN3ME2xOE43PDR6IN88US=>NH\vdZBUSU6JRWK=
C2BBe1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTF2Lke2OEDPxE1?NILDT3dUSU6JRWK=
EM-2NYDOO|RWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTF2Lki1O|Yh|ryPMXfTRW5ITVJ?
HCC1395MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nxVmlEPTB;MUSuPVM{QCEQvF2=NIrTfJlUSU6JRWK=
A2058NV;3dHVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfOflZ6UUN3ME2xOU4xPDB7IN88US=>MXfTRW5ITVJ?
SW1463M2TRNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1LRN2lEPTB;MUWuNFQ5PSEQvF2=Mn\vV2FPT0WU
J82NHXVUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonYTWM2OD1zNT6wOVch|ryPNGTOfo1USU6JRWK=
CAL-120NEjH[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTF3LkG0OFch|ryPMne4V2FPT0WU
COLO-824NHTqeW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInYZZBKSzVyPUG1MlE2PzlizszNMUPTRW5ITVJ?
LNCaP-Clone-FGCMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTF3LkSyOFgh|ryPNVH5UWZpW0GQR1XS
CP66-MELNIDjVHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRTF3LkS2PFgh|ryPNITlS2lUSU6JRWK=
OC-314NFPQflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXEO41KSzVyPUG1MlQ4OTRizszNNWjoR5IyW0GQR1XS
OVCAR-8M4\obWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTF3Lki4OlEh|ryPM2HhfHNCVkeHUh?=
MFE-280Mn7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHPeGFKSzVyPUG2MlA1QDhizszNNVm2UVl4W0GQR1XS
MHH-NB-11NV25UpBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPFfIRKSzVyPUG2MlA5OzlizszNMWTTRW5ITVJ?
SW1990NFjVS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIDLVVRKSzVyPUG2MlE4PTVizszNNFzCbWNUSU6JRWK=
U-266NVn3WFJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULSOZVSUUN3ME2xOk4zOjl7IN88US=>MUfTRW5ITVJ?
MFM-223MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTF4LkO5OlUh|ryPMoPlV2FPT0WU
L-363M{T0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoC5TWM2OD1zNj60OVc4KM7:TR?=MXPTRW5ITVJ?
MCF7MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzITWM2OD1zNj60O|I{KM7:TR?=NH\0[mVUSU6JRWK=
SK-MEL-3NVPvRVczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDvTWM2OD1zNj60O|g4KM7:TR?=M{HsWHNCVkeHUh?=
HHNXr6SpRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlrmTWM2OD1zNj61NVYzKM7:TR?=MUPTRW5ITVJ?
no-10MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnLVY5UUUN3ME2xOk43OzR|IN88US=>MVHTRW5ITVJ?
HuP-T3M3LVUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NID6TFdKSzVyPUG2MlY2PzZizszNMl\hV2FPT0WU
QIMR-WILMonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTF4LkexNFUh|ryPNVX5eVAxW0GQR1XS
NCI-H1092MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWjKUGh4UUN3ME2xOk45OzF4IN88US=>NETLWnJUSU6JRWK=
MZ2-MELNWPlWWJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{TzfmlEPTB;MU[uPFQxOyEQvF2=NXuzOplEW0GQR1XS
ES3NELUc2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rJ[mlEPTB;MU[uPVE{PCEQvF2=MV\TRW5ITVJ?
COLO-684MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTF4Lkm0O|ch|ryPNXz5[YpnW0GQR1XS
NCI-H661NUjWdllKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;lOmx{UUN3ME2xOk46Pjl2IN88US=>MkXvV2FPT0WU
CP50-MEL-BNYTkWGxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFnoeIVKSzVyPUG3MlA{PDNizszNMmrkV2FPT0WU
NCI-H2405MkHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFrxZ4dKSzVyPUG3MlE6PzRizszNNFrKNJZUSU6JRWK=
U-2-OSNXXLSVQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHJWndKSzVyPUG3MlU{ODdizszNM3XTd3NCVkeHUh?=
RERF-LC-MSNYKyTXU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\mUGlEPTB;MUeuOVUxQCEQvF2=NWi5[2U1W0GQR1XS
NCI-H2342MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTF5LkW1O{DPxE1?NV3tWoRYW0GQR1XS
ES8NHrwdHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULSN2FVUUN3ME2xO{43ODh5IN88US=>MkC0V2FPT0WU
MOLT-16M4[3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlK3TWM2OD1zNz64PVM1KM7:TR?=NGS1dG1USU6JRWK=
RH-18NEXtRnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV7Pc2o6UUN3ME2xPE4xODN3IN88US=>NUftUZNpW0GQR1XS
D-283MEDMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1zkfGlEPTB;MUiuNFA5QCEQvF2=MVrTRW5ITVJ?
RCC10RGBNECwcFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXX5dHU4UUN3ME2xPE4xPTV7IN88US=>M1:xWXNCVkeHUh?=
NCI-H1437NGq4eGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTF6LkG2OFEh|ryPNHX1foZUSU6JRWK=
SW982NV6wU|BzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTF6LkK2O|Eh|ryPM1zxPXNCVkeHUh?=
IST-MES1NXT2U|BlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnXJTWM2OD1zOD60OFI5KM7:TR?=NYHoOnl3W0GQR1XS
A704MmnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{[0PGlEPTB;MUiuOFc2OyEQvF2=M{DaXXNCVkeHUh?=
ESS-1MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrsTWM2OD1zOD61NlA2KM7:TR?=M3XkR3NCVkeHUh?=
SCHMmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILUeGNKSzVyPUG4MlY1PTZizszNMn;MV2FPT0WU
COLO-320-HSRMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlzCTWM2OD1zOD63OFYh|ryPMX7TRW5ITVJ?
Mo-TM{LGOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\UXZZ6UUN3ME2xPE45OjB2IN88US=>MmHXV2FPT0WU
Saos-2MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;EUWlEPTB;MUmuNVE3OiEQvF2=NYnE[FNsW0GQR1XS
SW684NVTvWVJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jaNmlEPTB;MUmuNVMzPiEQvF2=MUDTRW5ITVJ?
KMOE-2NFXZUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWXoZnRFUUN3ME2xPU4zOjR{IN88US=>M2L0dXNCVkeHUh?=
MMAC-SFMnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTF7LkK2NFch|ryPNFfGUWxUSU6JRWK=
JARMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVe2O5l5UUN3ME2xPU4zQTlizszNMoW4V2FPT0WU
SK-MEL-28NIfzfZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnkXFBKSzVyPUG5MlM{PjNizszNMnr5V2FPT0WU
KNS-81-FDNIHoSoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TnZmlEPTB;MUmuOVQ3QCEQvF2=MV3TRW5ITVJ?
ES7NYqxOHRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fCVmlEPTB;MUmuOlI6OiEQvF2=MYfTRW5ITVJ?
AsPC-1NIP5c5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTOeVY1UUN3ME2xPU43PDdzIN88US=>NETVZWtUSU6JRWK=
NCI-H1155M4HS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFuwVJJKSzVyPUG5MlczOzhizszNMlrnV2FPT0WU
KYSE-510MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTF7Lki3OFgh|ryPM{SzTnNCVkeHUh?=
ES1NUnsbGJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUPObWppUUN3ME2xPU46OjF|IN88US=>NG\adZJUSU6JRWK=
PC-3MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnPTWM2OD1zOT65OlA1KM7:TR?=NEH5W5VUSU6JRWK=
GCTNX;nRVZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1HCV2lEPTB;MkCuN|AzPiEQvF2=MYHTRW5ITVJ?
KARPAS-299MlzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTJyLkO0NlIh|ryPNGLMU2JUSU6JRWK=
DOHH-2NXjOdpZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTJyLkW0OlMh|ryPMWjTRW5ITVJ?
COLO-741MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3sTWM2OD1{MD62OkDPxE1?NGe0bJhUSU6JRWK=
NCI-H1395NVzrO4NVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\MdZFKSzVyPUKwMlY3QTdizszNM3fydnNCVkeHUh?=
HCC1187NYrtO3JQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUHVfng5UUN3ME2yNE43PzN2IN88US=>NXXCPGFGW0GQR1XS
BeckerMmX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTJyLkeyNFEh|ryPNX3YcXFVW0GQR1XS
LU-134-AM3zXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWLNWnNEUUN3ME2yNU4yODJ4IN88US=>MmfUV2FPT0WU
MKN45NF\vfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\DNmlEPTB;MkGuNVU2OSEQvF2=NWTqc2oyW0GQR1XS
LC-2-adM320OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIS1fGlKSzVyPUKxMlI4OjlizszNMkPjV2FPT0WU
EW-24M3XjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPiUYJLUUN3ME2yNU4{QTR3IN88US=>MojwV2FPT0WU
SK-N-ASNIXC[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1rucGlEPTB;MkGuPFI4PiEQvF2=MYnTRW5ITVJ?
NCI-H2052M2WzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPWWGJKSzVyPUKxMlg6PjNizszNM3rqPXNCVkeHUh?=
A4-FukMlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXviVYFtUUN3ME2yNk4yPDF7IN88US=>NELzSYVUSU6JRWK=
NB10Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrTN2pKSzVyPUKyMlI{PzFizszNNEizR2dUSU6JRWK=
CHP-212NHG4[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTJ{LkOyNlIh|ryPMlf6V2FPT0WU
KM12NHPMcHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{nVTWlEPTB;MkKuN|U3KM7:TR?=NFu2fFNUSU6JRWK=
JEG-3MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17NRWlEPTB;MkKuN|c5KM7:TR?=MWfTRW5ITVJ?
LN-405MkfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTJ{LkW5NVMh|ryPMoXZV2FPT0WU
HCT-15MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH7BXotKSzVyPUKyMlc1PDFizszNNHfzfJVUSU6JRWK=
MLMAMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zqe2lEPTB;MkKuO|Q4KM7:TR?=M37IOnNCVkeHUh?=
GI-1M4m3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX31VIpUUUN3ME2yNk44PjV6IN88US=>MX3TRW5ITVJ?
RT-112NV7leXJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PhbGlEPTB;MkKuPFYyPiEQvF2=NGLKWoFUSU6JRWK=
MPP-89NXTPS5lET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXOTWM2OD1{Mj64OlYyKM7:TR?=MYXTRW5ITVJ?
A3-KAWMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlrCTWM2OD1{Mz6xNFA{KM7:TR?=NXjWRlZIW0GQR1XS
KALS-1NIP6O4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MomzTWM2OD1{Mz6xOFE1KM7:TR?=MVHTRW5ITVJ?
SF126NYHXSmVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXm0coRYUUN3ME2yN{43QTJ2IN88US=>M1;EV3NCVkeHUh?=
SiHaMlG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmrBTWM2OD1{Mz65N|I4KM7:TR?=NEnoWmZUSU6JRWK=
MDA-MB-415MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{Dpb2lEPTB;MkOuPVQ6QSEQvF2=MYTTRW5ITVJ?
DaoyMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmTSTWM2OD1{ND6xNlYh|ryPNVzOd|dVW0GQR1XS
COR-L23NGnE[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3PPUGlEPTB;MkSuNVc3PyEQvF2=MofpV2FPT0WU
KG-1M4rFNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TufGlEPTB;MkSuNVkzQCEQvF2=MlLmV2FPT0WU
L-428M2XtNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYL3VWZ3UUN3ME2yOE42PzlzIN88US=>Mo[wV2FPT0WU
NCI-H520NITDSVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnFRpBsUUN3ME2yOE45QDZzIN88US=>MlzoV2FPT0WU
COLO-792MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoPQTWM2OD1{NT6yO|MzKM7:TR?=M3zKXXNCVkeHUh?=
NB12NF25bFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU[wZ3ZXUUN3ME2yOU4zQTR5IN88US=>M{XXTHNCVkeHUh?=
GAKNYPlfIJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUT4dXZ[UUN3ME2yOU4zQTZ|IN88US=>NXyzZXNRW0GQR1XS
SW780NEf5eXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTJ3LkOyOlQh|ryPMUTTRW5ITVJ?
GB-1NWfZ[Y1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTJ3LkSwOlkh|ryPMYLTRW5ITVJ?
P12-ICHIKAWANVfxR4xUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHxTWM2OD1{NT60O|g2KM7:TR?=NIPTbnlUSU6JRWK=
NCI-H1651NHTIPXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn:4TWM2OD1{NT61PVch|ryPMYXTRW5ITVJ?
KE-37Mly5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF20NIVKSzVyPUK1Mlc{OTVizszNNX\GSJpyW0GQR1XS
CCRF-CEMNUDqb2R[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;wXGlEPTB;MkWuPVY4KM7:TR?=NVSx[olwW0GQR1XS
SF295MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLJTWM2OD1{Nj6wOFI2KM7:TR?=NVvLOll6W0GQR1XS
G-361M3HhWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTJ4LkGwNlch|ryPNFXOXJVUSU6JRWK=
HOP-92MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTJ4LkGyNlYh|ryPMXrTRW5ITVJ?
UMC-11MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\pWmlEPTB;Mk[uOFUyPCEQvF2=MoDYV2FPT0WU
IST-SL1NFzLNYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHlbnF7UUN3ME2yOk43PTlzIN88US=>NWnJ[Gh1W0GQR1XS
TE-11NGHJbplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XPb2lEPTB;Mk[uO|c2OiEQvF2=NHrTS3RUSU6JRWK=
NCI-H1304MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTDSHFiUUN3ME2yOk46OTB6IN88US=>M{nzXXNCVkeHUh?=
SJSA-1NW\teIpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjZ[2FKSzVyPUK3MlAyPzZizszNMWnTRW5ITVJ?
BCPAPM3O3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fDemlEPTB;MkeuNVM4KM7:TR?=MojSV2FPT0WU
HTC-C3M3juSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2W5UGlEPTB;MkeuNlU3OSEQvF2=NUjBZnlbW0GQR1XS
EW-16M3\XSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDRflFKSzVyPUK3MlI6PDdizszNM1XSSXNCVkeHUh?=
HT-144NVj6d3BxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWO3S3JWUUN3ME2yO{41ODN{IN88US=>MkK0V2FPT0WU
MHH-ES-1MnrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjQN2NKSzVyPUK3MlQ1PDdizszNMVzTRW5ITVJ?
T98GMmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2Gxc2lEPTB;MkeuOVg1PiEQvF2=M4\mb3NCVkeHUh?=
RPMI-8866NVLXWFNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPHTWM2OD1{Nz63OVYzKM7:TR?=NVvzT4YxW0GQR1XS
BENNYT3enhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3jLNGlEPTB;MkeuPFUyPyEQvF2=M2PBNXNCVkeHUh?=
MDA-MB-231Ml:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PB[WlEPTB;MkiuNlc6PSEQvF2=MkT3V2FPT0WU
HuH-7MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\qTWM2OD1{OD60NFI5KM7:TR?=NX;SNpQyW0GQR1XS
SK-N-FINYPj[VRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE[wd2NKSzVyPUK4MlQ{OyEQvF2=M3HWTHNCVkeHUh?=
AN3-CAMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIjLRmlKSzVyPUK4MlQ{QTVizszNNV7HS4pmW0GQR1XS
EGI-1M3f5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;hTWM2OD1{OD61PVI5KM7:TR?=M2D5[HNCVkeHUh?=
697NWPYNYc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTJ6Lk[zN|Eh|ryPMlTiV2FPT0WU
TCCSUPMm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTJ6Lk[0NVgh|ryPNYjpXmtTW0GQR1XS
GR-STMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DOWGlEPTB;MkiuOlY6PiEQvF2=NH\QcYVUSU6JRWK=
SK-N-DZMkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\HfWlEPTB;MkiuOlg5PSEQvF2=NICyVFhUSU6JRWK=
MIA-PaCa-2NGi2WIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTJ6Lke5OVkh|ryPNVTWbll6W0GQR1XS
IGR-1M1PqVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTJ6Lki4O|Qh|ryPMWrTRW5ITVJ?
BFTC-905M1Pqdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XlO2lEPTB;MkmuNlcxPSEQvF2=M4DidHNCVkeHUh?=
NCI-H1581NWLhfnRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17EdmlEPTB;MkmuN|E1PSEQvF2=NUX0N49oW0GQR1XS
RDNUHOPWN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mly4TWM2OD1{OT61NlM{KM7:TR?=MWXTRW5ITVJ?
SF268MkLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1rWbWlEPTB;MkmuOVk{OSEQvF2=NEj6Z|lUSU6JRWK=
SHP-77MkLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTJ7Lk[xPFIh|ryPNIHkZ5dUSU6JRWK=
D-566MGNVThfYFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHwWZVxUUN3ME2yPU46Ozl|IN88US=>NYDab21iW0GQR1XS
TGBC1TKBMoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3K4d2lEPTB;M{CuNVI{QCEQvF2=Mlu4V2FPT0WU
MEL-HONWXUXoxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTNyLkG0NlMh|ryPM4LYWXNCVkeHUh?=
SJRH30NHH5SYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTNyLkKxNFgh|ryPM3XpcHNCVkeHUh?=
D-336MGMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV22TWZlUUN3ME2zNE4zQDl{IN88US=>NETCNIdUSU6JRWK=
C3ANHrobXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTNyLkK5Nlch|ryPNH;WZWNUSU6JRWK=
Calu-6M{DZb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XFeGlEPTB;M{CuNlk3OyEQvF2=NU\yN2FwW0GQR1XS
MZ1-PCMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnHbWhKSzVyPUOwMlM6OyEQvF2=MYDTRW5ITVJ?
KYSE-70MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\WN5RkUUN3ME2zNE42OTF2IN88US=>MkHZV2FPT0WU
CAPAN-1M{TtOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrjTWM2OD1|MD61NVgyKM7:TR?=M1X3SnNCVkeHUh?=
DK-MGNHPUfWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTNyLkW0OVYh|ryPNVzkZ25nW0GQR1XS
SK-HEP-1NXS1UWVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\oO2lEPTB;M{CuOlMzPiEQvF2=NGTGcGdUSU6JRWK=
MS-1M{H5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{Due2lEPTB;M{CuPFg5QSEQvF2=NGTkXpRUSU6JRWK=
GI-ME-NM13tUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFznUWZKSzVyPUOxMlA2PzFizszNNXXLXGhuW0GQR1XS
NCI-H510ANX\neIp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXGTWM2OD1|MT60NFA3KM7:TR?=NI\RXXJUSU6JRWK=
NB17MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTNzLkWxPFUh|ryPM{XKT3NCVkeHUh?=
639-VMoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PrRmlEPTB;M{GuOVI1OyEQvF2=MoewV2FPT0WU
CAL-51NXn1PGlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTNzLkW2Olch|ryPNFPRWlVUSU6JRWK=
HGC-27NVPLXG5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;J[JMzUUN3ME2zNU42QDd|IN88US=>M2XlNnNCVkeHUh?=
GOTOM1v0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHzTWM2OD1|MT64OVA3KM7:TR?=NUjXR5hsW0GQR1XS
ChaGo-K-1MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUj6T3RiUUN3ME2zNk4xODdizszNNWLGOWZ7W0GQR1XS
RO82-W-1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHzXnVKSzVyPUOyMlE3ODRizszNNXLYZVU4W0GQR1XS
SH-4M1:2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXS0W2tJUUN3ME2zNk4yQDV6IN88US=>MXXTRW5ITVJ?
A204NFSzV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXrhW493UUN3ME2zNk42ODZ7IN88US=>Mme2V2FPT0WU
DMS-273NXj3NoZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTN{LkWzNlIh|ryPMULTRW5ITVJ?
KGNM4K2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTN{Lk[zN{DPxE1?MWPTRW5ITVJ?
SK-MEL-2MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTN{Lk[1Nlch|ryPNG\IcnlUSU6JRWK=
NCI-H2228MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33ZTmlEPTB;M{KuOlYxOiEQvF2=M1LueHNCVkeHUh?=
MKN28MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrPfWZUUUN3ME2zNk44QDN6IN88US=>NVzKbZNPW0GQR1XS
H-EMC-SSNEXzXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml:1TWM2OD1|Mj65Olc5KM7:TR?=MmnsV2FPT0WU
ATN-1NXjIWlZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4X5d2lEPTB;M{OuNVQyPiEQvF2=M1;IU3NCVkeHUh?=
D-263MGNVO5NlFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHlTWM2OD1|Mz64N|c5KM7:TR?=MYrTRW5ITVJ?
LU-135NYDYd242T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXRRnF7UUN3ME2zN{45QDJ7IN88US=>NVvzSZBkW0GQR1XS
C8166M{TScmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfJe4VKSzVyPUOzMlg5PTRizszNMnywV2FPT0WU
T-24NEHaSFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzRcIR7UUN3ME2zOE4xOjB3IN88US=>MkjLV2FPT0WU
MewoNVu1Tmt7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGniRWhKSzVyPUO0MlE{PDlizszNM4nvNXNCVkeHUh?=
22RV1NXzGN4d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTN2LkG3OVQh|ryPMVfTRW5ITVJ?
KM-H2MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnKwTWM2OD1|ND6xO|c6KM7:TR?=NGDDWXVUSU6JRWK=
NCI-H2122MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\kWWlEPTB;M{SuN|Q4OSEQvF2=MVnTRW5ITVJ?
ABC-1NVXyd4JtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXf5NJNLUUN3ME2zOE4{Pjl|IN88US=>MluwV2FPT0WU
NCI-H1355M{i3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\yPHR1UUN3ME2zOE4{QDh7IN88US=>M{G1WnNCVkeHUh?=
NOMO-1M3zhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MonaTWM2OD1|ND61O|A{KM7:TR?=M4LMdnNCVkeHUh?=
MZ7-melMorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvNS3RFUUN3ME2zOE43PDh5IN88US=>MUfTRW5ITVJ?
NCI-H810MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\yTWM2OD1|ND63Nlc5KM7:TR?=MoXXV2FPT0WU
D-392MGM3[4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn2yTWM2OD1|NT6wOVY2KM7:TR?=NW\IXYNSW0GQR1XS
LB771-HNCNFH4NZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVe3bFF1UUN3ME2zOU4yPjV6IN88US=>NVnKSXR[W0GQR1XS
COLO-679NFPhbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrDTWM2OD1|NT6zPFgh|ryPNFfDSIdUSU6JRWK=
SK-PN-DWNUHkZopxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHnsVGdKSzVyPUO1MlQ{PjlizszNNUTZTYs6W0GQR1XS
VA-ES-BJNIL3[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1[3bGlEPTB;M{WuOFY1QSEQvF2=MVHTRW5ITVJ?
KNS-42NYO2UlVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTN3LkW4NlYh|ryPNHywUJBUSU6JRWK=
RVH-421MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn\2TWM2OD1|NT63OlQ2KM7:TR?=MV3TRW5ITVJ?
P30-OHKM2DL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XrXWlEPTB;M{WuPFc2OiEQvF2=NIS1WpdUSU6JRWK=
G-402NYXBdYJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnn1TWM2OD1|NT65PFY4KM7:TR?=M2jPSnNCVkeHUh?=
S-117MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jKTmlEPTB;M{[uN|AxQCEQvF2=NVLjbWNTW0GQR1XS
RXF393MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVT5c5JXUUN3ME2zOk4{Pzh3IN88US=>NEG4d2hUSU6JRWK=
LCLC-103HNVHKWmpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYP5W4JlUUN3ME2zOk44QDB|IN88US=>MoXBV2FPT0WU
U-118-MGNV3jfIJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTN4Lki4OFch|ryPMlXtV2FPT0WU
8-MG-BANX\FU|JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTN4Lkm0PFMh|ryPNFrZWpdUSU6JRWK=
MFH-inoNWjqdVhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2f2WGlEPTB;M{euN|M4OSEQvF2=NYXwU4ljW0GQR1XS
NCI-H23MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzFTWM2OD1|Nz60NVk3KM7:TR?=NH;lWWlUSU6JRWK=
NCI-H446M3e3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M363d2lEPTB;M{euOFg3OiEQvF2=M{HoSXNCVkeHUh?=
LU-99ANGG3UmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTN5LkW3N|Eh|ryPNI\KcZpUSU6JRWK=
KP-N-YNNFLXTG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTN5Lk[xPVUh|ryPMnvFV2FPT0WU
SCC-9MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XRVGlEPTB;M{euO|g{QCEQvF2=NUXXeHFJW0GQR1XS
EFM-19MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTN5Lke5Olch|ryPNUTBPItYW0GQR1XS
A427NETPTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkHiTWM2OD1|Nz65NVA4KM7:TR?=NUm4cWV7W0GQR1XS
LB831-BLCMl\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnPTWM2OD1|OD62NFM6KM7:TR?=MmXSV2FPT0WU
HOSMmrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NELkdIFKSzVyPUO5MlYzPzNizszNM1jWOXNCVkeHUh?=
LAN-6M37Qcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTRyLkCxNVIh|ryPNGDQdoJUSU6JRWK=
U251MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTRyLkSwOVQh|ryPMVnTRW5ITVJ?
SNU-387M2XOPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrtTWM2OD12MD60OVU{KM7:TR?=MVPTRW5ITVJ?
DMS-79NHW3U5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4fUfWlEPTB;NECuOVg5QSEQvF2=M17TTHNCVkeHUh?=
SK-LU-1M{D3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPmTWM2OD12MD62OVY5KM7:TR?=M2ruV3NCVkeHUh?=
HTNFXI[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTRyLk[2N|kh|ryPMnm4V2FPT0WU
KP-N-YSMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTRyLk[3Olgh|ryPMorFV2FPT0WU
DMS-114MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTRyLkizO|Qh|ryPMkH6V2FPT0WU
HUTU-80NE\BOohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvKUHJQUUN3ME20NU4xPTZ7IN88US=>MX;TRW5ITVJ?
ONS-76NVziWo5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXETllKSzVyPUSxMlQ4ODlizszNMWrTRW5ITVJ?
A673NFrxbmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEfJXZhKSzVyPUSxMlUyPTdizszNNETWcoFUSU6JRWK=
HPAF-IIMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3wO3BtUUN3ME20NU43PzB7IN88US=>MX\TRW5ITVJ?
UACC-257MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13CcGlEPTB;NEGuO|M3QSEQvF2=M2Cz[3NCVkeHUh?=
EW-22MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTRzLki2PVch|ryPM4m3U3NCVkeHUh?=
NCI-H1755M2O3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3ZfW1KSzVyPUSxMlg4OjVizszNM{j1T3NCVkeHUh?=
KYSE-150NInuRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLuTWM2OD12Mj6xO|gzKM7:TR?=M{C3eHNCVkeHUh?=
CGTH-W-1NXH4XmR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfkT5ZKSzVyPUSyMlQ6PTVizszNMm\aV2FPT0WU
NB13M1rDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTR{Lk[yNVch|ryPMWDTRW5ITVJ?
SW872NFfUcWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXpTWM2OD12Mj62N|MyKM7:TR?=M2fQUnNCVkeHUh?=
KP-4MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHIWpFpUUN3ME20Nk45QDN{IN88US=>Ml34V2FPT0WU
HCC38MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVnoPVFHUUN3ME20Nk46PjF6IN88US=>NFjDSI5USU6JRWK=
BB49-HNCM1TlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGntfXNKSzVyPUSzMlI{PTZizszNMUPTRW5ITVJ?
CAL-62M4Lpb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEj6PYhKSzVyPUSzMlQxOjhizszNNVjtcWRqW0GQR1XS
NCI-H2029MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTR|LkW1PFEh|ryPMUfTRW5ITVJ?
M14NELPSI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkO4TWM2OD12ND6xN|MzKM7:TR?=Mo\XV2FPT0WU
COLO-680NMmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH2xR5FKSzVyPUS0MlM{QSEQvF2=MknrV2FPT0WU
Hs-578-TMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33xW2lEPTB;NEWuNFI6PCEQvF2=NEP1W5pUSU6JRWK=
MSTO-211HMn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkLhTWM2OD12NT65OFgzKM7:TR?=MkXjV2FPT0WU
EW-1MlXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHnXNXBKSzVyPUS1Mlk3QDlizszNM{n6W3NCVkeHUh?=
SW948M2fiNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmfaTWM2OD12Nj60OFYzKM7:TR?=MV;TRW5ITVJ?
NCI-H460Mo\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlG3TWM2OD12Nj61NlMh|ryPNIn0OYVUSU6JRWK=
CAS-1M2DMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLnTWM2OD12Nj63O|AyKM7:TR?=NIDWWllUSU6JRWK=
TGBC11TKBMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnOTWM2OD12Nz6xO|c4KM7:TR?=M321ZXNCVkeHUh?=
HD-MY-ZMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTZTWM2OD12OD63PFYh|ryPNGSwdlhUSU6JRWK=
NCI-H226MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTR7Lke3PFUh|ryPNHqwT3VUSU6JRWK=
PA-1NWf5UG5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTR7LkizN|Uh|ryPMUDTRW5ITVJ?
LB2518-MELNHvDc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUL6eFhKUUN3ME20PU45PzJ|IN88US=>NVXTNVdVW0GQR1XS
A101DNHHKe5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rMSWlEPTB;NEmuPVQzPSEQvF2=NW\TNpZWW0GQR1XS
NCI-H2087MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlfZTWM2OD12OT65OlgzKM7:TR?=M4jBNHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Daily oral administration of BIBW2992 at 20 mg/kg for 25 days results in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%. Reduced phosphorylation of EGFR and AKT is confirmed by immunohistochemical staining of tissue sections. Therefore, like lapatinib and neratinib, BIBW2992 is a next generation tyrosine kinase inhibitor (TKI) that inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases irreversibly. BIBW2992 is not only active against EGFR mutations targeted by first generation TKIs like Erlotinib or Gefitinib, but also against those insensitive to these standard therapies. [1]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

In vitro kinase activity assays The wild type tyrosine kinase domain of the human EGFR as well as that of the EGFR L858R/T790M double mutant are fused to Glutathione-S-transferase (GST), and extracted. Enzyme activity is then assayed in the presence of the inhibitor BIBW2992, serially diluted in 50% DMSO. A random polymer pEY (4:1) is used as substrate and biotinylated pEY (bio-pEY) is added as a tracer substrate. The kinase domain of HER2 is cloned using the baculovirus system and extracted similarly to that of EGFR kinase. Details of assays for EGFR, HER2, SRC, BIRK and VEGFR2 kinase activity are available in Supplementary information.

Cell Assay:

[1]

Cell lines NSCLC cells
Concentrations 0-10 μM
Incubation Time 1 hour
Method

1 × 104 NSCLC cells are transferred into each well of a 96-well plate and cultured overnight in serum-free media for the EGFR phosphorylation assay. After addition of BIBW2992 on the next day, the plates are incubated at 37 °C for 1 hour. EGF-stimulation is done using 100 ng/mL for 10 min at room temperature. Cells are washed with ice cold PBS, extracted with 120 μL HEPEX buffer per well and shaken at room temperature for 1 hour. In all 2 × 104 cells per well is used for the HER2 phosphorylation assay. Streptavidin precoated plates are coated with anti-EGFR-biotin at 1:100 dilution in blocking buffer and c-erb2/HER2 oncoprotein Ab-5(Clone N24)-Biotin. Cell extracts is then transferred to the antibody-coated wells and incubated at room temperature for 1 hour. Extinction is measured at 450 nm.

Animal Study:

[1]

Animal Models Athymic NMRI-nu/nu female mice
Formulation In 0.5% methocellulose-0.4% polysorbate-80 (Tween 80)
Dosages 20 mg/kg
Administration Oral administration

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Li D, et al. Oncogene, 2008, 27(34), 4702-4711.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-23)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02795156 Not yet recruiting Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma SCRI Development Innovations, LLC|Foundation Medicine|Boe  ...more SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer July 2016 Phase 2
NCT02780687 Not yet recruiting Urologic Neoplasms Boehringer Ingelheim June 2016 Phase 2
NCT02183883 Not yet recruiting Non-small Cell Lung Cancer University College, London|Boehringer Ingelheim May 2016 Phase 2
NCT02716311 Not yet recruiting Non Small Cell Lung Cancer Intergroupe Francophone de Cancerologie Thoracique April 2016 Phase 2
NCT02501603 Not yet recruiting Gastric Cancer|Gastroesophageal Junction Cancer Yonsei University March 2016 Phase 2

view more

Chemical Information

Download Afatinib (BIBW2992) SDF
Molecular Weight (MW) 485.94
Formula

C24H25ClFN5O3

CAS No. 439081-18-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 97 mg/mL (199.61 mM)
Ethanol 15 mg/mL (30.86 mM)
Water <1 mg/mL (<1 mM)
In vivo 0.5% methylcellulose+0.2% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (S,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide

Customer Product Validation(3)


Click to enlarge
Rating
Source Int J Proteomics 2011 2011, 215496. Afatinib (BIBW2992) purchased from Selleck
Method CEER assay
Cell Lines H460/A549/RFU cell lines
Concentrations 0-10 μM
Incubation Time 4 h
Results This data showed that a potent dose-dependent inhibition of the HER1 and HER2 pathways in the HCC827 cells was observed by treatment with BIBW-2992. Other HER1 and/or HER2 pathway-activated cell lines, H1975 and H1650, were likewise had these pathway activations blocked by the treatment with BIBW-2992.

Click to enlarge
Rating
Source Int J Proteomics 2011 2011, 215496. Afatinib (BIBW2992) purchased from Selleck
Method Nikon inverted-phase microscope
Cell Lines lung tumor cell lines
Concentrations 0.1/1 µM
Incubation Time two weeks
Results Reduction of cell colony size formation was observed by the treatment with the irreversible HER1/2 inhibitor BIBW-2992 in H1975 and H1650 cells as seen when these cells were grown in an anchorage-dependent manner.

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. Afatinib (BIBW2992) purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-1 nM
Incubation Time 3 h
Results BIBW2992 treatment resulted in a reduction of EGFR phosphorylation in Breast cancer cells.

Frequently Asked Questions

  • Question 1
    What’s the recommendation about reconstitution of the compound for in vivo animal study?

    Answer: For in vivo experiment of afatinib, we recommend 0.5% methylcellulose/0.2% Tween 80 as vehicle.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related EGFR Products

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Afatinib (BIBW2992) Dimaleate

    Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

  • Poziotinib (HM781-36B)

    Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.

  • Gefitinib (ZD1839)

    Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

    Features:A potent EGFR tyrosine kinase inhibitor.

  • Erlotinib HCl (OSI-744)

    Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Osimertinib (AZD9291)

    Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

  • Lapatinib

    Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

  • AG-490 (Tyrphostin B42)

    AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

  • Rociletinib (CO-1686, AVL-301)

    Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays, respectively. Phase 2.

  • AG-1478 (Tyrphostin AG-1478)

    AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Recently Viewed Items

Tags: buy Afatinib (BIBW2992) | Afatinib (BIBW2992) ic50 | Afatinib (BIBW2992) price | Afatinib (BIBW2992) cost | Afatinib (BIBW2992) solubility dmso | Afatinib (BIBW2992) purchase | Afatinib (BIBW2992) manufacturer | Afatinib (BIBW2992) research buy | Afatinib (BIBW2992) order | Afatinib (BIBW2992) mouse | Afatinib (BIBW2992) chemical structure | Afatinib (BIBW2992) mw | Afatinib (BIBW2992) molecular weight | Afatinib (BIBW2992) datasheet | Afatinib (BIBW2992) supplier | Afatinib (BIBW2992) in vitro | Afatinib (BIBW2992) cell line | Afatinib (BIBW2992) concentration | Afatinib (BIBW2992) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us